Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 12Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 14Lymphoid 13Myeloid 8Plasma cell 7Genitourinary 6Sarcoma 5Dermatologic 4Gastrointestinal 3Breast 3Tumor-Agnostic 2Thoracic 2Gynecologic 2Classical hematology 2Head & Neck 1CNS 1

Conditions

Recurrent Uterine Sarcoma 1Ovarian Neoplasms 1

Interventions

Paclitaxel 69Carboplatin 66Cisplatin 36pembrolizumab 34Gemcitabine 24liposomal doxorubicin 23Cyclophosphamide 23Topotecan 22Bevacizumab 20Taxes 14Docetaxel 13niraparib 12Nivolumab 12olaparib 10fludarabine 10Doxorubicin 9Surveys and Questionnaires 8Radiotherapy 8Oxaliplatin 8aldesleukin 7Filgrastim 7rucaparib 6oregovomab 6fludarabine phosphate 6durvalumab 6avelumab 6Interleukin-2 6Hyperthermic Intraperitoneal Chemotherapy 6Fluorodeoxyglucose F18 6Cytoreduction Surgical Procedures 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Sirolimus × Gynecologic × Clear all
NCT03456700 2025-05-08

Auranofin and Sirolimus in Treating Participants With Ovarian Cancer

Mayo Clinic

Phase 2 Terminated
22 enrolled 9 charts
Gynecologic

Ovarian Neoplasms

NCT01061606 2016-11-09

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

National Cancer Institute (NCI)

Phase 2 Terminated
8 enrolled 6 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡